Drug intelligence / Profile preview

surgiGRAFT AC

Development stage: Unknown
Lead developer: Synergy Biologics
Modality: Cell Therapies
Administration: Topical, Surgical Graft/implantation

Overview

surgiGRAFT AC is a dehydrated dual-layer amnion/chorion membrane allograft developed by Synergy Biologics. Classified as a Human Cell, Tissue, and Cellular or Tissue-Based Product (HCT/P) under 21 CFR Part 1271, it is derived from amniotic tissue recovered from healthy donors during cesarean childbirth. The allograft serves as a surgical graft and tissue barrier that supports healing by providing a regenerative extracellular matrix rich in signaling factors and proteins. It possesses anti-inflammatory, anti-scarring, and anti-microbial properties, facilitating the development of granulation tissue in acute and chronic wounds, such as incisional dehiscence.

Brand names: surgiGRAFT AC
Other names: dehydrated dual-layer amnion/chorion allograft

Beyond the preview

Go deeper on surgiGRAFT AC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on surgiGRAFT AC.

Explore the full profile